Method for detecting severity of atopic dermatitis

Patent metadata

Field	Value
Publication number	US-2024018593-A1
Application number	US-202118038915-A
Country	US
Kind code	A1
Filing date	Nov 29, 2021
Priority date	Nov 30, 2020
Publication date	Jan 18, 2024
Grant date	—

Abstract

Provided are a marker for detecting the severity of atopic dermatitis and a method for detecting the severity of atopic dermatitis using the marker.

First claim

1 . A method for detecting severity of systemic eruption by atopic dermatitis in a subject, the method comprising:
measuring an expression level of a marker for detecting severity of systemic eruption by atopic dermatitis in a subject, wherein the marker for detecting severity of systemic eruption by atopic dermatitis is at least one selected from the group consisting of following genes: TWF1 ADAM15, and SETD1B, and expression products of the genes, wherein the severity is severity of atopic dermatitis corresponding to Excema Area and Severity Index.

2 . The method according to claim 1 , further comprising detecting severity of systemic eruption by atopic dermatitis in the subject based on the expression level of the marker.

3 .- 12 . (canceled)

13 . The method according to claim 1 , wherein the marker is at least one selected from the group consisting of the following genes: TWF1, ADAM15, CIZ1, AND SETD1B and expression products of the genes, and the higher the expression level of the marker is, the worse the severity of systemic eruption by atopic dermatitis in the subject is detected.

14 . (canceled)

15 . The method according to claim 1 , comprising measuring the expression level of the marker in the subject at different time points.

16 . The method according to claim 15 , wherein
the marker is at least one selected from the group consisting of the following genes: TWF1, ADAM15, CIZ1, an SETD1B, and expression products of the genes, and when the measured expression level of the marker in the subject is higher than the expression level in the subject at previous measurement, the severity of systemic eruption by atopic dermatitis in the subject is detected to be exacerbated, or when the measured expression level of the marker in the subject is lower than the expression level in the subject at previous measurement, the severity of systemic eruption by atopic dermatitis in the subject is detected to be remitted.

17 .- 33 . (canceled)

34 . The method according to claim 1 , wherein the marker is a nucleic acid marker.

35 . The method according to claim 34 , wherein the nucleic acid is mRNA collected from skin surface lipids.

Assignees

• Kao Corp

Inventors

• Takada Naoto
• Kuwano Tetsuya
• Inoue Takayoshi

Classifications

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• G01N2800/202

  Dermatitis · CPC title